<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of mild to moderate ulcerative colitis in children and adolescents</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of mild to moderate ulcerative colitis in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of mild to moderate ulcerative colitis in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Athos Bousvaros, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess L Kaplan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melvin B Heyman, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis (UC) and Crohn disease (CD). These disorders have distinct pathologic and clinical characteristics  (<a class="graphic graphic_table graphicRef74564" href="/z/d/graphic/74564.html" rel="external">table 1</a>), but their pathogenesis remains poorly understood. (See  <a class="medical medical_review" href="/z/d/html/4066.html" rel="external">"Definitions, epidemiology, and risk factors for inflammatory bowel disease"</a>.)</p><p>Approximately 20 percent of patients with CD and 12 percent of those with UC develop symptoms before 20 years of age [<a href="#rid1">1</a>]. The development of IBD early in life has implications that are not encountered in adults. Clinicians caring for children and adolescents with CD or UC not only must treat the underlying disease and its complications but must also carefully monitor linear growth, skeletal development, and puberty, as well as how the child's maturation and psychological health are affected by living with a chronic disease. In addition, some therapies used for older patients cannot be applied to young children, because many children are unable to swallow pills or refuse enema therapy.</p><p>The treatment of UC in children and adolescents is reviewed here. Other aspects of the diagnosis and management of children with UC are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>UC in children principally occurs in teenagers but can also occur earlier in life [<a href="#rid2">2</a>]. The presentation in children is similar to that in adults. Affected patients usually present with a subacute illness characterized by diarrhea frequently containing blood, weakness, anemia, abdominal pain, and sometimes weight loss. Those with a more fulminant presentation (acute severe UC) also may have severe abdominal pain, frankly bloody diarrhea, tenesmus, fever, leukocytosis, and hypoalbuminemia. Some children have more insidious onset of symptoms, with nonbloody diarrhea and sometimes poor weight gain prior to the development of more overt symptoms or signs [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/5893.html" rel="external">"Growth failure and pubertal delay in children with inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Clinical manifestations'</a>.)</p><p>Children with UC are more likely than adults to present with pancolitis (approximately 80 percent in children versus 40 to 50 percent in adults) [<a href="#rid4">4</a>]. Younger children with inflammatory bowel disease (IBD; ie, those presenting prior to six years of age) are more likely to present with isolated colonic disease, and distinguishing between UC and Crohn disease (CD) may be more difficult in this age group [<a href="#rid5">5-8</a>]. Young children typically present with rectal bleeding. Older children are more likely to present with abdominal pain, weight loss, and fever, in addition to bleeding [<a href="#rid7">7</a>]. There are no clear differences in disease severity and clinical course among children presenting with IBD between one and six years of age compared with those presenting after six years [<a href="#rid9">9</a>]. By contrast, cases presenting in infancy have a distinct clinical course that is often more severe because such cases are often related to immunodeficiencies or other causes of "monogenic IBD." (See  <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Very early-onset inflammatory bowel disease'</a>.)</p><p>Extraintestinal manifestations of IBD may precede the gastrointestinal symptoms and are somewhat different in UC as compared with CD, as outlined in the table  (<a class="graphic graphic_table graphicRef88092" href="/z/d/graphic/88092.html" rel="external">table 2</a>) and described in detail separately [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Extraintestinal manifestations'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">PROCTITIS</span><span class="headingEndMark"> — </span>Patients with disease limited to the rectum (ie, inflammation that extends no more than 15 cm proximal to the anal verge) are good candidates for receiving topical therapy.</p><p>Moderately active inflammation is treated best initially with a topical 5-aminosalicylate (5-ASA; eg, <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a>) enema or suppository preparation; a topical (rectal) <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> enema, foam, or suppository; or <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> enema. A combination of topical and oral mesalamine is also useful in inducing remission and may be necessary if topical therapy alone is ineffective [<a href="#rid11">11</a>]. In patients who have not responded to topical aminosalicylates, topical corticosteroid preparations can be utilized for induction of remission, although evidence from pediatric studies is lacking. Topical budesonide can treat proctosigmoiditis effectively and may have fewer side effects than conventional glucocorticoids. If topical administration of medication is not possible due to parent or child refusal, oral administration of a 5-ASA medication is a reasonable alternative, although oral 5-ASA usually requires more frequent dosing and is probably less effective than topical 5-ASA for proctitis. (See  <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease", section on '5-ASA formulations'</a>.)</p><p>Less commonly, immunosuppressive therapy (with immunomodulators or biologics) or colectomy is required for refractory proctitis. Most such therapy involves systemic immunosuppression (eg, anti-tumor necrosis factor [anti-TNF]), but there are also case reports describing use of <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> enemas in adults and children [<a href="#rid12">12,13</a>]. (See  <a class="medical medical_review" href="/z/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Ulcerative proctitis or proctosigmoiditis'</a> and  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis", section on 'Subsequent steps for steroid-refractory disease'</a>.)</p><p>Once a patient's symptoms are controlled, patients should be transitioned to a maintenance aminosalicylate (rectal or oral), so that corticosteroids may be discontinued, to minimize long-term corticosteroid toxicity [<a href="#rid14">14</a>]. The choice of medication and route of administration depends on the child and family's preference and on the patient's individual responsiveness to the treatment. In some patients, transition to oral aminosalicylate therapy may result in relapse of the proctitis, which requires the reinstitution of rectal treatment. (See  <a class="medical medical_review" href="/z/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a>.)</p><p>Relapses in proctitis may be caused by poor adherence to therapy or to proximal extension of the disease over time. As an example, in an observational study in 149 children with ulcerative proctitis, 49 percent had colonic extension of disease at last follow-up; the risk for extension was 10, 45, and 52 percent at 1, 5, and 10 years, respectively [<a href="#rid15">15</a>]. Similarly, in a separate study of children with ulcerative proctitis, the risk for proximal extension to left-sided colitis or pancolitis was 54 percent among those followed for more than five years [<a href="#rid16">16</a>]. Thus, patients with proctitis should be reevaluated endoscopically if they have recurrent or refractory symptoms.</p><p>Relapses in proctitis also may be triggered by an enteric infection, especially <em>Clostridioides</em> <em>difficile</em>. Therefore, patients presenting with a flare of proctitis or colitis should be screened for bacterial causes of colitis, with stool cultures and testing for <em>C. difficile</em> toxin. (See  <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Stool testing for enteric pathogens'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">LEFT-SIDED DISEASE AND PANCOLITIS</span><span class="headingEndMark"> — </span>For patients with mild or moderate colitis, medical therapy usually is successful in achieving remission and often maintains long-term remission as well. The basic principles of medical therapy are similar to those in adults with UC, although the chronic use of glucocorticoids in children is particularly problematic because of potential linear growth impairment and bone demineralization. Thus, aminosalicylates or glucocorticoids are used for induction, depending on the severity of presentation  (<a class="graphic graphic_algorithm graphicRef112968" href="/z/d/graphic/112968.html" rel="external">algorithm 1</a>). The aim is to transition patients to aminosalicylate maintenance therapy. However, fewer than 50 percent of patients maintain corticosteroid-free remission on aminosalicylates alone [<a href="#rid17">17,18</a>]. The remainder of patients require long-term treatment with immunomodulators or biologic agents. (See <a class="local">'Subsequent management'</a> below.)</p><p>Management of children with severe or refractory colitis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis"</a>.)</p><p class="headingAnchor" id="H349555872"><span class="h2">Clinical assessment</span></p><p class="headingAnchor" id="H349555891"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of UC is made on the basis of clinical, laboratory, radiologic, and endoscopic/histologic information. Clinical manifestations are as described above (see <a class="local">'Clinical manifestations'</a> above). The steps in diagnosis, including the differentiation between UC and Crohn disease (CD), are described separately. In patients younger than six years who have features suggestive of monogenic inflammatory bowel disease (IBD)  (<a class="graphic graphic_table graphicRef99327" href="/z/d/graphic/99327.html" rel="external">table 3</a>), more extensive evaluation should be considered  (<a class="graphic graphic_algorithm graphicRef99328" href="/z/d/graphic/99328.html" rel="external">algorithm 2</a>) because management strategies may differ. (See  <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children"</a>.)</p><p class="headingAnchor" id="H349555755"><span class="h3">Disease severity</span><span class="headingEndMark"> — </span>Several measures are used to categorize disease activity. Measures based on clinical symptoms are sufficient for some medical decisions, but invasive testing (endoscopy) is more accurate and should be used during the initial evaluation, periodically thereafter, and any time that the results would potentially alter a significant medical decision.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical symptoms</strong> – A pediatric UC activity index (PUCAI) has been developed to assess the activity of disease  (<a class="graphic graphic_table graphicRef69607" href="/z/d/graphic/69607.html" rel="external">table 4</a>) (<a class="calc calc_professional" href="/z/d/html/122272.html" rel="external">calculator 1</a>) [<a href="#rid19">19</a>]. Numerical scores are given to symptoms of abdominal pain, rectal bleeding, stool consistency, stool frequency, presence of nocturnal stools, and activity level, adding to a maximum score of 85. Of these components, rectal bleeding has the greatest impact on the score, contributing up to 30 points.</p><p></p><p class="bulletIndent1">PUCAI scores are interpreted as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>0 to 9 – Remission</p><p class="bulletIndent2"><span class="glyph">•</span>10 to 34 – Mild disease</p><p class="bulletIndent2"><span class="glyph">•</span>35 to 64 – Moderate disease</p><p class="bulletIndent2"><span class="glyph">•</span>65 to 85 – Severe disease</p><p></p><p class="bulletIndent1">An alternative measure of clinical symptoms is <a class="external" href="/external-redirect?target_url=https%3A%2F%2Flp.vp4.me%2Fxnny&amp;token=C3c6oiaQK09VCj9WXDIkmVNgVqIpjTFNOsgEDY%2BWwuk%3D&amp;TOPIC_ID=5871" target="_blank">TUMMY-UC</a>, which is designed for direct report by the patient or caregiver and includes parameters similar to those of PUCAI [<a href="#rid20">20</a>]. In a validation study, TUMMY-UC scores had moderate to strong correlation with more invasive measures of disease activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endoscopic assessment</strong> – Endoscopic assessment of disease activity provides the most sensitive measure of healing and should be used periodically, in conjunction with the clinician assessment. The findings are typically categorized as follows (from the Mayo score):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mild colitis – Mild friability, erythema, decrease in vascularity</p><p class="bulletIndent2"><span class="glyph">•</span>Moderate colitis – Friability, marked erythema, vascular pattern absent, erosions seen</p><p class="bulletIndent2"><span class="glyph">•</span>Severe colitis – Ulcerations and spontaneous bleeding</p><p></p><p class="bulletIndent1">Endoscopic disease activity can predict the potential for disease relapse [<a href="#rid21">21</a>]. In pediatric patients, there is moderate correlation between endoscopic disease severity (Mayo score) and clinical disease activity (PUCAI) [<a href="#rid22">22</a>]. Similarly, three hematologic parameters (white blood count, platelet count, and sedimentation rate) correlate well with endoscopic inflammation [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H349555943"><span class="h3">Evaluation for infectious colitis</span><span class="headingEndMark"> — </span>Infectious etiologies or superimposed infections should be excluded by stool cultures for enteric pathogens (<em>Salmonella</em>, <em>Shigella</em>, <em>Yersinia</em>, <em>Campylobacter</em>, <em>Escherichia</em> <em>coli</em>, and if appropriate, <em>Amoeba</em>), as well as tests for <em>C. difficile</em> toxin. Although most colitis flares are not triggered by pathogenic bacterial infection, between 5 and 25 percent of children presenting with a flare of UC have underlying <em>C. difficile</em> [<a href="#rid24">24-26</a>]. In an immune-compromised patient, evaluation for cytomegalovirus infection should also be considered. Details of this evaluation to exclude other causes of colitis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H2017342917"><span class="h3">Determination of response to therapy</span><span class="headingEndMark"> — </span>The long-term aim of treatment is to induce a remission, including resolution of symptoms, normalization of inflammatory markers (C-reactive protein and calprotectin), normalization of growth, and mucosal healing of the colon as assessed by endoscopy, as outlined in guidance from the STRIDE group [<a href="#rid27">27</a>].</p><p>Accordingly, the response to therapy is typically determined by a combination of clinical symptoms (PUCAI) and laboratory testing, supplemented with endoscopy with biopsies when indicated:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PUCAI score</strong> – Changes in clinical symptoms should be monitored by determining the PUCAI score at each clinical encounter  (<a class="graphic graphic_table graphicRef69607" href="/z/d/graphic/69607.html" rel="external">table 4</a>) (<a class="calc calc_professional" href="/z/d/html/122272.html" rel="external">calculator 1</a>). The goal of therapy is complete resolution of symptoms, reflected by a PUCAI score of &lt;10. For patients with moderate or severe UC, a marked improvement in PUCAI (eg, PUCAI &lt;35 or a PUCAI decrease of ≥20 points) provides an initial indication of successful medical therapy  (<a class="graphic graphic_algorithm graphicRef112968" href="/z/d/graphic/112968.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood and stool tests</strong> – Laboratory tests should be monitored regularly, at least every three months during immunosuppressive therapy and at least annually for patients not on immunosuppressive agents. These tests should be interpreted in conjunction with clinical symptoms and in the context of the patient's historical results [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count (CBC), albumin, and C-reactive protein (CRP), or erythrocyte sedimentation rate (ESR).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional laboratory tests to monitor for comorbidities or adverse effects of drugs are typically performed at the same time, including alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGTP), as well as therapeutic drug monitoring for <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, or thiopurines. Therapeutic drug monitoring can also be considered for some of the newer biologics (<a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a>, <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>), though it is less established. (See <a class="local">'Thiopurines'</a> below and <a class="local">'Infliximab'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fecal markers of inflammation, such as lactoferrin and calprotectin, are also useful biomarkers of clinical response and mucosal healing [<a href="#rid28">28</a>]. For calprotectin, values &gt;250 mg/g are usually associated with significant mucosal inflammation and values &lt;100 mg/g generally reflect remission, although improvement in calprotectin may lag behind mucosal healing by several months [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Stool tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endoscopy</strong> – Endoscopic grading of disease severity is increasingly used for assessing response to therapy. Colonoscopy is recommended before making major changes in therapy or when it is unclear whether symptoms are disease-related [<a href="#rid26">26</a>]. Colonoscopy is not routinely indicated for mild or moderate relapses. During severe exacerbations of colitis, sigmoidoscopy may be indicated to exclude concomitant cytomegalovirus infection.</p><p></p><p class="bulletIndent1">When endoscopic grading is used to assess treatment response, the goal is improvement and/or resolution of the grossly visible signs of active colitis, such as friability, erythema, erosions, ulcerations, and bleeding. The most commonly utilized scoring system for this purpose is the endoscopy component of the Mayo score [<a href="#rid29">29</a>]. While a Mayo endoscopy subscore of 0 (no grossly visible disease activity at endoscopy) is the ideal goal of treatment, this is not always achievable. Alternatively, some experts have advocated that histologic remission (resolution of microscopic abnormalities) should be the ultimate treatment goal, but benefits of this stringent target are not established and the measure is complicated by sampling error and lack of consensus about definitions of abnormal histology [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1">Colonoscopy is also recommended for colorectal cancer surveillance, beginning 8 to 10 years after disease onset. For patients with IBD-associated primary sclerosing cholangitis, a European guideline suggests surveillance colonoscopy every one to two years, but this recommendation is based largely on data from adults [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Surveillance for cancer'</a>.)</p><p></p><p class="headingAnchor" id="H1824380255"><span class="h2">Initial management</span></p><p class="headingAnchor" id="H7"><span class="h3">Mild disease</span><span class="headingEndMark"> — </span>In patients with mild disease extending beyond the rectum (ie, fewer than four bowel movements daily without significant abdominal pain, anemia, or fever, and PUCAI score 10 to 34), we suggest a trial of oral 5-aminosalicylate (5-ASA; usually <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a> or <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>) as first-line therapy  (<a class="graphic graphic_algorithm graphicRef112968" href="/z/d/graphic/112968.html" rel="external">algorithm 1</a>) [<a href="#rid26">26</a>]. These drugs are moderately effective for mild disease and have fewer side effects than systemic glucocorticoids [<a href="#rid17">17</a>]. Combination therapy with oral and topical (rectal) 5-ASA should be used for induction of remission, if acceptable to the patient, because this is more effective than topical therapy alone [<a href="#rid26">26,32</a>]. Mild, left-sided disease may also respond to topical treatment alone (eg, mesalamine enemas), and a trial of this approach is reasonable in patients who are willing and adherent to enema treatment [<a href="#rid26">26</a>]. However, we find that most children and families prefer orally administered medications and are more likely to adhere to an oral regimen. (See  <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"</a>.)</p><p>Oral 5-ASA preparations include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mesalamine</strong> – <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">Mesalamine</a> (also known as mesalazine or unconjugated 5-ASA) is typically given at an oral dose of 60 to 80 mg/kg/day, divided twice or three times daily (up to the adult dose of 4.8 g/day) [<a href="#rid26">26</a>]. Some clinicians use mesalamine doses up to 100 mg/kg/day (maximum 4.8 g/day) for induction of remission in children, based on data extrapolated from trials in adults [<a href="#rid33">33</a>]. Limited information from studies in adults and children suggests that sustained-release preparations of mesalamine (Multi Matrix System [MMX] mesalamine) also are effective [<a href="#rid34">34</a>]. These preparations may increase adherence by reducing the frequency of dosing and have been approved in the United States for children weighing ≥24 kg [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sulfasalazine</strong> – <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a> is a prodrug composed of 5-ASA linked to sulfapyridine through an azo bond, which is split in the colon. It is given as an initial dose of 25 mg/kg/day divided twice or three times daily and advanced over one week to the full dose of 60 to 80 mg/kg/day divided twice or three times daily (up to a maximum dose of 4 g daily); some clinicians use doses above or below this range. In larger children and adults, initial doses are 1 to 2 g/day, titrated to 4 to 6 g/day, divided three to four times daily. Supplemental <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> (1 mg/day) should be given to all patients taking sulfasalazine. Sulfasalazine has the advantage that it can be compounded into a liquid and easily taken by children. However, <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a> and other 5-ASA agents have fewer side effects than sulfasalazine, including reduced headache and skin rashes. Sulfasalazine contains a sulfapyridine component that can trigger allergic reactions (including rare cases of Stevens-Johnson syndrome) in patients with sulfa hypersensitivity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Balsalazide</strong> – <a class="drug drug_general" data-topicid="8713" href="/z/d/drug information/8713.html" rel="external">Balsalazide</a> is split in the colon by colonic bacteria, releasing <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a>. Typical doses in children are 75 to 100 mg/kg/day divided three times daily, up to a maximum dose of 6.75 g divided three times daily in larger children or adults. In adults, the initial dose is typically given for eight weeks, then reduced to a maintenance dose of 3 to 4 g daily, divided into two doses. The adult dose cited above was used in a small clinical trial in children 5 to 17 years of age; there were no significant differences in adverse effects or efficacy as compared with a smaller dose of 2.25 g/day, but this may have been because of the small size of the trial [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease", section on '5-ASA formulations'</a>.)</p><p></p><p>Few studies have compared the efficacy of different aminosalicylates in children. Most experiences in children have been with <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a> or <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, but these drugs have not been directly compared. In our practice, we often use mesalamine as the first-line choice because sulfasalazine has a higher risk for allergic reactions and side effects, such as photosensitivity, due to the sulfonamide component. However, sulfasalazine has the advantage of lower cost and is a reasonable alternative in patients without a history of sulfa sensitivity, provided that <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> supplements are also given. Also, sulfasalazine may be helpful in managing IBD-associated arthritis, if present [<a href="#rid26">26</a>].</p><p>Most children over five years of age can learn how to swallow pills. Techniques for learning to swallow pills, including practicing with small pieces of food or candy, are outlined on a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.crohnscolitisfoundation.org%2Fsites%2Fdefault%2Ffiles%2Flegacy%2Fassets%2Fpdfs%2FPillSwallowing.pdf&amp;token=y5vJiO3eIFINhdf3Z01CYXruSMHY9LEtC9baCOYnORA7NxFlEYLX%2BloSM1UNLpenATMWbPI7JAp6XDZRLlYClX8u8Iogxu2yn3eCOYN38mbTqnFBwSRdjDBweVIzN7ti&amp;TOPIC_ID=5871" target="_blank">tip sheet</a> from the Crohn's and Colitis Foundation. Options for children who cannot swallow pills despite this training include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">Mesalamine</a> capsules (eg, Pentasa) – These capsules can be opened into water or acidic food (consumed immediately and without chewing).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8713" href="/z/d/drug information/8713.html" rel="external">Balsalazide</a> capsules – These capsules can be opened and sprinkled onto applesauce. The mixture may be chewed and should be swallowed promptly. It should not be stored for future use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a> – Sulfasalazine tablets can be made into a suspension by a compounding pharmacy.</p><p></p><p>Slight exacerbation of watery diarrhea is common during the first few weeks of therapy with 5-ASA preparations and particularly with <a class="drug drug_general" data-topicid="9717" href="/z/d/drug information/9717.html" rel="external">olsalazine</a> and <a class="drug drug_general" data-topicid="8713" href="/z/d/drug information/8713.html" rel="external">balsalazide</a> [<a href="#rid37">37</a>]. In addition, approximately 3 percent of patients treated with <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a> have a paradoxical worsening of their colitis symptoms (acute mesalamine intolerance), with increased cramps, diarrhea, and rectal bleeding, usually developing within the first month of treatment. Recurrence on rechallenge confirms the diagnosis of mesalamine intolerance; in this case, 5-ASA agents should no longer be used. (See  <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease", section on '5-aminosalicylic acid (5-ASA)'</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Moderate disease</span><span class="headingEndMark"> — </span>Patients with moderate disease (PUCAI score of 35 to 64) typically have more than four bloody bowel movements per day and intermittent abdominal pain but no tenesmus or fever. The most common approach for patients with moderate symptoms is a course of systemic glucocorticoids, especially if systemic symptoms such as fever or anorexia are present. However, for patients who are reluctant to use glucocorticoids, it is reasonable to offer a trial of 5-ASA, similar to patients with milder disease, using doses at the high end of the range (see <a class="local">'Mild disease'</a> above). A third option that is used for selected patients at some centers is early use of a biologic agent (typically in hospitalized patients using <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>), similar to the approach for patients with more severe disease. (See <a class="local">'Infliximab'</a> below and <a class="local">'Adalimumab'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral glucocorticoids</strong> – For patients with frequent stools and mild or moderate abdominal pain, we suggest oral glucocorticoid therapy  (<a class="graphic graphic_algorithm graphicRef112968" href="/z/d/graphic/112968.html" rel="external">algorithm 1</a>). <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> (1 to 1.5 mg/kg once daily, to a maximum of 40 to 60 mg/day) usually induces remission [<a href="#rid26">26</a>]. Steroid-responsive patients usually show some clinical signs of improvement within one week of starting treatment.</p><p></p><p class="bulletIndent1">Oral <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> has been suggested as an alternative to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> because it has fewer side effects. Budesonide MMX extends the release of drug in the colon and has been shown to effectively treat moderate disease; dosing for children &gt;30 kg is 9 mg daily for eight weeks [<a href="#rid38">38,39</a>]. Although budesonide has fewer side effects than prednisone, chronic use can still lead to significant steroid-associated toxicity. (See  <a class="medical medical_review" href="/z/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Induction of remission'</a>.)</p><p></p><p class="bulletIndent1">The full dose of oral glucocorticoid usually is continued for two to three weeks, then gradually tapered over the next 8 to 10 weeks. The oral glucocorticoid is usually combined with <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a> (or another 5-ASA), which can be started during the glucocorticoid treatment course (see <a class="local">'Subsequent management'</a> below). Some patients respond to steroids very quickly, and in this case, the taper can be started somewhat sooner. For <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> MMX, which is formulated in 9-mg capsules, we taper by dosing every two days, then every three days, before stopping.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous glucocorticoids</strong> – For patients who are unresponsive to oral glucocorticoid therapy within one to two weeks or those with poor fluid intake, severe abdominal pain, vomiting, and/or poor nutrition, we suggest hospitalization and intravenous glucocorticoids  (<a class="graphic graphic_algorithm graphicRef112968" href="/z/d/graphic/112968.html" rel="external">algorithm 1</a>). Bowel rest and intravenous fluids have not been shown to hasten remission but may relieve symptoms of abdominal cramping associated with oral intake and decrease stool frequency.</p><p></p><p class="bulletIndent1">Dosing and duration of therapy depends on the severity of symptoms and response to treatment and is based on clinical experience because of lack of precise clinical evidence, as outlined in consensus guidelines [<a href="#rid26">26</a>]. Typical management in our practice is:</p><p></p><p class="bulletIndent1">We initiate treatment with <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (1 mg/kg per dose, given every 12 hours to a maximum of 40 to 60 mg/day).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Practice varies among experts regarding the timing of transition to oral glucocorticoids. In our practice, we transition to oral glucocorticoids approximately 24 to 48 hours after noting a definite clinical response to treatment (eg, PUCAI &lt;35 or a PUCAI decrease of ≥20 points).</p><p></p><p class="bulletIndent2">We start oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at 1 to 2 mg/kg/day (maximum of 40 to 60 mg/day). This dose usually is continued for two to four weeks, then gradually tapered over the next two months. The oral glucocorticoid is usually combined with <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a> (or another 5-ASA). (See <a class="local">'Maintenance of remission'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with no clear response to treatment after five days of intravenous therapy, we initiate an evaluation for other potential contributing factors and a discussion of second-line therapies, including colectomy and medical therapies (<a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, calcineurin inhibitors) for steroid-refractory or acute severe colitis. Flexible sigmoidoscopy is helpful in this setting in order to gather more information on disease activity and to search for concomitant infection with cytomegalovirus, which, if found, could significantly alter treatment. (See  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis", section on 'Pretreatment evaluation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with partial response to intravenous therapy (eg, some improvement, but PUCAI remains &gt;35), we may continue intravenous treatment for up to two weeks before moving on to second-line therapies. The timeline for making this decision varies substantially in clinical practice. (See  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis", section on 'Subsequent steps for steroid-refractory disease'</a> and  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis", section on 'Initial therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics</strong> – Some clinicians utilize systemic antibiotic therapy empirically in the treatment of colitis flares (typically for patients with steroid-refractory or steroid-dependent disease). Because evidence on this practice is limited, guidelines do not support antibiotic use as a routine option in UC [<a href="#rid26">26</a>]. However, a few reports, including a small observational study in children, suggest that broad-spectrum oral antibiotics are sometimes effective, though long-term outcomes are not well known [<a href="#rid40">40,41</a>]. Therefore, an empiric trial of antibiotics may be appropriate in selected cases in which 5-ASA and glucocorticoids are not effective or are rejected by the patient [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H349548858"><span class="h2">Subsequent management</span></p><p class="headingAnchor" id="H349548864"><span class="h3">Maintenance of remission</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>5-ASA</strong> – For patients who achieve remission of their colitis through the above interventions, maintenance with a 5-ASA agent is preferred [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thiopurines</strong> – Patients who are intolerant of, or do not remain in remission with, a 5-ASA agent alone can be treated with mercaptopurine (also known as <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a> [6-MP]) or <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> (AZA) [<a href="#rid26">26,43,44</a>]. However, the benefits of using these immunosuppressive agents as maintenance therapy must be weighed against the risks (infection, lymphoma) and compared with the benefits and risks of anti-tumor necrosis factor (anti-TNF) agents or colectomy. Colectomy has the benefit of removing the disease and allowing discontinuation of immunosuppression [<a href="#rid45">45</a>]. While there is some support for the early use of thiopurines in children with CD, at least one retrospective study did not find support for early introduction of AZA (&lt;6 months after diagnosis) compared with later AZA initiation (6 to 24 months after diagnosis) in children with UC [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis"</a> and  <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/z/d/html/1375.html" rel="external">"Surgical management of ulcerative colitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biologics</strong> – Increasingly, biologics (especially anti-TNF agents such as <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>) have displaced thiopurines as maintenance therapy in children with mild to moderate IBD that cannot be kept in remission with aminosalicylates. While biologics are much more expensive than thiopurines, they may carry a lower risk of lymphoma. Dosing and other considerations are outlined below. (See <a class="local">'Infliximab'</a> below and <a class="local">'Adalimumab'</a> below.)</p><p></p><p class="bulletIndent1">Other biologic and small-molecule therapies used to treat UC in adults (<a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a>, <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a>, <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a>) are sometimes used off-label in children. (See <a class="local">'Second-line options'</a> below and <a class="local">'Other options'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – While probiotics are commonly taken by patients with UC and prescribed by some clinicians, their efficacy for UC remains unproven. VSL#3 may have some efficacy in treating active disease as an adjunctive approach. Details of these and other studies are discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/2603.html" rel="external">"Probiotics for gastrointestinal diseases", section on 'Ulcerative colitis'</a>.)</p><p></p><p class="bulletIndent1">Curcumin is an extract of turmeric root that appears to have a protective role in a mouse model of UC, purportedly by modulating the release of tumor necrosis factor-alpha (TNF-alpha) and nitric oxide. One study suggests that it is tolerated well in children [<a href="#rid47">47</a>].</p><p></p><p class="headingAnchor" id="H349548995"><span class="h3">Steroid-dependent disease</span><span class="headingEndMark"> — </span>Patients are considered to be steroid-dependent if they have been on high-dose glucocorticoids for more than two to three months or daily glucocorticoids for four to six months, or frequently flare when the glucocorticoid dose is reduced (eg, two or three relapses per year). For such patients, we suggest transitioning to a thiopurine or biologic agent to avoid the high morbidity associated with prolonged glucocorticoid therapy [<a href="#rid26">26,44</a>]. The optimal approach has not been established, and either approach is reasonable.</p><p>For patients with steroid-dependent disease, we suggest maintenance therapy with either <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, or a thiopurine. Considerations are outlined below.</p><p class="headingAnchor" id="H2308973575"><span class="h4">Infliximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a> is another first-line option and a reasonable alternative to a thiopurine for maintenance therapy in patients with steroid-dependent disease. The main rationale for choosing infliximab over thiopurines as maintenance is the concern about an increased relative risk of lymphoma associated with thiopurine use. However, the absolute risk of lymphoma with thiopurines is very low, and some patients prefer thiopurines because of the oral rather than parenteral administration.</p><p><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a> is a highly effective anti-TNF agent that is US Food and Drug Administration (FDA) approved for pediatric UC in children six years and older. Many clinicians are using it instead of immunomodulators to treat corticosteroid refractory colitis because evidence suggests that infliximab monotherapy does not increase the risk of lymphoma [<a href="#rid48">48</a>]. The routine dose is 5 mg/kg given at zero, two, and six weeks, then every eight weeks. The initial response rate to infliximab in children with UC is approximately 70 percent after eight weeks (three doses of therapy), but the long-term remission rate after one year is approximately 30 percent [<a href="#rid48">48,49</a>]. Increasing the dose of infliximab (to 10 mg/kg/dose), reducing the interval of infliximab infusions (to every four to six weeks), and therapeutic drug monitoring may increase the response to infliximab. (See  <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">"Medical therapies for Crohn disease in children and adolescents", section on 'Monitoring infliximab levels and antibodies'</a>.)</p><p>In adults, combination therapy with AZA and <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> has been shown to be more effective than using either agent alone [<a href="#rid50">50</a>]. The benefit of this approach must be weighed against the rare risk of lymphoma, including hepatosplenic T cell lymphoma. However, anti-TNF agents are not risk-free. Their risks include opportunistic infection (particularly lung infections), infusion reactions, development of anti-drug antibodies, loss of response, skin complications including psoriasis, and rare neurologic conditions, such as demyelination or weakness.</p><p class="headingAnchor" id="H10045277"><span class="h4">Adalimumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">Adalimumab</a> is also a first-line option for maintenance therapy in children with steroid-dependent disease. It is approved in the United States for children five years and older with UC. Recommended doses are:</p><p class="bulletIndent1"><span class="glyph">●</span>Children 20 to 40 kg:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Induction – 80 mg on day 1, 40 mg on day 8, and 40 mg on day 15</p><p class="bulletIndent2"><span class="glyph">•</span>Maintenance – 40 mg every two weeks (or 20 mg weekly)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children ≥40 kg:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Induction – 160 mg (as a single dose or split over two consecutive days) on day 1, 80 mg on day 8, and 80 mg on day 15</p><p class="bulletIndent2"><span class="glyph">•</span>Maintenance – 80 mg every two weeks (or 40 mg weekly)</p><p></p><p>Of note, this dosing schedule is more frequent than used for children with CD.</p><p>The approval of <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> for pediatric UC was based on the ENVISION trial, the results of which have not been published but are available in abstract form and in the manufacturer's prescribing information. In this study of 93 patients with moderate to severe UC, adalimumab induced clinical response and sustained remission in at least 40 percent of subjects, with safety signals similar to those in adults [<a href="#rid51">51,52</a>]. Prior case series in children also reported successful use as a second-line biologic therapy [<a href="#rid53">53,54</a>]. (See  <a class="medical medical_review" href="/z/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults", section on 'Tumor necrosis factor inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis", section on 'Anti-tumor necrosis factor agents'</a>.)</p><p class="headingAnchor" id="H4185299690"><span class="h4">Thiopurines</span><span class="headingEndMark"> — </span>Some expert clinicians prefer to transition to thiopurines rather than <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> because of the loss of response over time seen with infliximab [<a href="#rid55">55,56</a>]. Thiopurines should not be used for induction of remission. The therapeutic effect typically increases gradually during the first two to three months of therapy. It may be helpful to continue 5-ASA therapy concomitantly, if tolerated. If a patient has been in remission for 6 to 12 months, the clinician can review the risks and benefits of discontinuing the aminosalicylate and leaving the patient on thiopurine monotherapy. One study in adults suggests that the efficacy or thiopurine monotherapy is similar to that of combination treatment with thiopurines and aminosalicylates [<a href="#rid57">57</a>].</p><p>Prior to initiating treatment with either 6-MP or AZA, it is important to measure the patient's thiopurine methyltransferase activity (TPMT phenotype) and/or genotype (TPMT genotype) [<a href="#rid19">19</a>]. This is because approximately 10 percent of individuals are heterozygotes for a TPMT mutation and are at risk for toxicity if standard dosing of these drugs are used. Moreover, approximately 0.3 percent of individuals are homozygotes for a TPMT mutation, in which case treatment with either 6-MP or AZA is contraindicated because of a high risk for bone marrow suppression. (See  <a class="medical medical_review" href="/z/d/html/4058.html" rel="external">"Thiopurines: Pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease"</a>.)</p><p>In patients with normal TPMT activity or genotype, we dose 6-MP at 1 to 1.5 mg/kg/day or AZA at 2 to 3 mg/kg/day. In one nonrandomized study, the addition of 6-MP permitted the discontinuation of glucocorticoids in 75 percent of 20 children [<a href="#rid43">43</a>]. In an observational study that included nearly 1500 children with UC, 50 percent of those treated with 6-MP or AZA were in remission without glucocorticoids one year later [<a href="#rid58">58</a>]. Only subjects without previous or concomitant treatment with biologic agents or calcineurin inhibitors (<a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) were included in this study.</p><p>All patients treated with 6-MP or AZA should undergo routine monitoring for the possible toxicities of bone marrow suppression and hepatotoxicity. We use the same approach to monitoring as for patients with CD:</p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring to detect bone marrow toxicity and hepatotoxicity. (See  <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">"Medical therapies for Crohn disease in children and adolescents", section on 'Safety and monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of 6-MP metabolite levels during therapy in selected patients to optimize drug therapy and limit toxicity. In particular, measurement of metabolite levels is useful in patients who have developed toxicity during treatment or in those who are not responding to what is believed to be a therapeutic dose of 6-MP or AZA. (See  <a class="medical medical_review" href="/z/d/html/4058.html" rel="external">"Thiopurines: Pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease"</a>.)</p><p></p><p>Like other immunomodulators or biologic agents, treatment with 6-MP or AZA increases a patient's susceptibility to bacterial, fungal, and viral infections. We suggest pretreatment screening for tuberculosis and special considerations for vaccines, as outlined in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Infection risk'</a> and  <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Immunizations'</a>.)</p><p class="headingAnchor" id="H4127782664"><span class="h4">Sequential or combination therapy</span><span class="headingEndMark"> — </span>For patients with steroid-dependent disease who do not respond to thiopurines, it is common practice to transition to <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> therapy. As an example, in the large trial cited above, approximately one-half of the subjects had been treated with thiopurines before proceeding to the trial of infliximab [<a href="#rid49">49</a>]. Similarly, for patients who do not respond to infliximab, it is common practice to offer treatment with a second biologic agent (eg, <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a>). Although this type of sequential therapy is common, the risks and benefits compared with proceeding to colectomy have not been assessed. We suggest explicit consideration of colectomy for patients who have failed infliximab or any other biologic agent. (See <a class="local">'Second-line options'</a> below.)</p><p>The use of combination therapy in pediatric UC (thiopurines simultaneously with <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>) is more controversial, though there are good data from the adult literature to support improved control of colitis [<a href="#rid50">50,59</a>]. The potential risks and benefits of this approach are probably similar to those for patients with CD. (See  <a class="medical medical_review" href="/z/d/html/120380.html" rel="external">"Medical therapies for Crohn disease in children and adolescents", section on 'Anti-TNF monotherapy versus combination therapy with an immunomodulator'</a>.)</p><p class="headingAnchor" id="H2659637654"><span class="h4">Second-line options</span><span class="headingEndMark"> — </span>For glucocorticoid-dependent patients who do not respond to therapy with thiopurines or <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> or who develop an adverse event (ie, pancreatitis), either surgery or alternate medical therapy can be offered. These second-line options are not approved by the FDA for children with UC ("off-label use"), but they may be appropriate for selected patients based on individual characteristics and if recommended by an expert clinician [<a href="#rid60">60</a>]. (See <a class="local">'Medical necessity of off-label use of medications in pediatrics'</a> below.)</p><p>Options supported by expert consensus and clinical experience include [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colectomy</strong> – Colectomy should be discussed as an option and is appropriate in patients who wish to avoid taking immunosuppressive agents or who cannot be weaned off <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> despite immunomodulator or <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> therapy. (See  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis", section on 'Surgery'</a> and  <a class="medical medical_review" href="/z/d/html/1375.html" rel="external">"Surgical management of ulcerative colitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vedolizumab</strong> – <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">Vedolizumab</a>, a gut-selective alpha-4-beta-7 integrin antibody, has been FDA approved in adults with moderate to severe UC, although time to remission was more gradual than for other biologic agents [<a href="#rid61">61</a>]. In one observational study, 80 percent of anti TNF-naïve patients had reached clinical remission at week 6 [<a href="#rid62">62</a>]. Endoscopic remission was seen in 59 percent of anti-TNF-naïve versus 15 percent anti-TNF-exposed patients [<a href="#rid63">63</a>]. Due to this relatively slow response to induction therapy, corticosteroids may be used as a bridge therapy while transitioning from failed treatment with anti-TNF-alpha. Small retrospective studies in adults describe apparent benefit of utilizing a calcineurin inhibitor for induction and bridging to vedolizumab [<a href="#rid64">64</a>]. In treatment-naïve adults with UC, vedolizumab was superior to <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> in achieving endoscopic remission (29 versus 11 percent) [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Vedolizumab'</a>.)</p><p></p><p class="bulletIndent1">Observational studies report clinical benefit with <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a> in some children [<a href="#rid62">62,63,66,67</a>]. Patients previously exposed to anti-TNF agents (<a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>) seem to have somewhat lower rates of clinical and endoscopic remission compared with treatment-naïve patients, similar to findings in adults. While this is a new agent, there is good evidence that the short-term safety profile is highly favorable [<a href="#rid26">26,62</a>]. While dosing of vedolizumab has not been formally established in children under 18, practicing clinicians typically utilize a dose of approximately 6 mg/kg to 10 mg/kg per infusion (maximum 300 mg). (See  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis", section on 'Subsequent steps for steroid-refractory disease'</a> and  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Vedolizumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Golimumab</strong> – <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">Golimumab</a>, an anti-TNF agent, has been FDA approved for induction and maintenance in adults with UC. It has the convenience of subcutaneous dosing (ie, no infusion necessary) and once-monthly dosing. Pediatric data are limited, though studies are underway. The adult dosing regimen is 200 mg for the initial dose, 100 mg two weeks later, then 100 mg every four weeks. A phase 1b study observed stable trough levels of golimumab in pediatric UC patients at these doses [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults", section on 'Tumor necrosis factor inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Anti-tumor necrosis factor (TNF) agent-based therapy'</a>.)</p><p></p><p class="headingAnchor" id="H2248062813"><span class="h4">Other options</span><span class="headingEndMark"> — </span>Several other medications have been used for children with steroid-dependent UC but appear to be less effective than biologics (<a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>) or are still experimental:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methotrexate</strong> – <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> is another immunomodulator and has been used for patients who are intolerant of or unresponsive to 6-MP or AZA, but it has not been investigated extensively in UC. While methotrexate was commonly used in the past off-label as a maintenance agent for UC, trials in adults found no superiority to placebo [<a href="#rid69">69,70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thalidomide</strong> – <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">Thalidomide</a> treatment for UC was evaluated in a small, randomized trial in 26 pediatric patients with UC that was refractory to various other immunosuppressive regimens [<a href="#rid71">71</a>]. Thalidomide treatment resulted in significantly higher rates of clinical remission at eight weeks of treatment (83 percent for thalidomide versus 18.8 percent for placebo) and longer maintenance of remission (135 weeks for thalidomide versus eight weeks for placebo). Thalidomide is thought to work through inhibition of TNF-alpha production and has demonstrated some promise as second- or third-line therapy in a small trial of refractory pediatric CD [<a href="#rid72">72</a>]. However, due to thalidomide's known potential adverse effects and risk of teratogenesis, the FDA has limited its use through a restricted distribution program.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tofacitinib</strong> – <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">Tofacitinib</a> (a Janus kinase [JAK] inhibitor) has been shown to be effective in adults with moderate to severe UC, but there is limited evidence in children. Compared with <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a>, it has more rapid onset of action but more safety concerns, which include risks for major adverse cardiac events [<a href="#rid73">73</a>], as well as deep vein thrombosis and pulmonary embolism with higher doses of tofacitinib. Tofacitinib is approved for treatment of pediatric rheumatoid arthritis and is available in a suspension, but it is not yet approved by the FDA for pediatric IBD.</p><p></p><p class="bulletIndent1">Data on <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> in children are limited to small case series [<a href="#rid74">74,75</a>]. As an example, in a retrospective report of 21 adolescents and young adults with moderate to severe UC or colonic IBD that was refractory to one or more other biologic agents, 48 percent had a clinical response to tofacitinib by week 6 [<a href="#rid74">74</a>]. For acute severe UC, a case-control study in adults found that the combination of high-dose tofacitinib with intravenous glucocorticoids was associated with substantially lower colectomy rates compared with glucocorticoids alone [<a href="#rid76">76</a>]. The experience with tofacitinib in adults is described separately. (See  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Janus kinase (JAK) inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">Upadacitinib</a> – Upadacitinib is a selective JAK 1 inhibitor that is FDA approved for the treatment of UC in adults. A theoretical benefit over <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a> is that the selectivity for one JAK protein may allow for higher dosing with fewer side effects (eg, lymphopenia). While experience in hospitalized severe UC is limited, upadacitinib is utilized as a second- or third-line agent for treating moderate to severe UC that has not responded to anti-TNF therapy. Evidence for benefit is based on randomized trials in adults and anecdotal evidence in children. Upadacitinib has been approved for treatment of atopic dermatitis in children 12 years and above, and a case report describes its use in a child with refractory CD [<a href="#rid77">77</a>]. Potential risks include cardiac adverse events, thromboembolism, and myelosuppression, similar to tofacitinib. (See  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Janus kinase (JAK) inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ustekinumab</strong> – <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a> is a human monoclonal antibody targeting p40 subunit of interleukin-12 and interleukin-23. It is FDA approved for the treatment of adults with moderate to severe UC [<a href="#rid78">78</a>]. Small retrospective studies in children suggest efficacy and safety similar to those in adults, but larger prospective studies are needed to confirm these observations [<a href="#rid79">79,80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcineurin inhibitors</strong> – Case series have described the use of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> as "rescue therapy" for patients with severe or refractory UC, but these agents have little role in moderate disease. (See  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis", section on 'Subsequent steps for steroid-refractory disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fecal microbiota transplantation (FMT)</strong> – Preliminary data suggest that FMT has the potential to be an effective and safe treatment for some UC patients when standard treatments have failed. Most data are from small trials in adults. However, studies in children with UC are limited to small patient cohorts, most of whom have recurrent <em>C</em>.<em> difficile</em> infection. We do not recommend FMT in patients with UC unless they either have <strong>comorbid</strong> recurrent <em>C. difficile</em> infection or are enrolled in a clinical trial. (See  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Investigational therapies'</a>.)</p><p></p><p class="headingAnchor" id="H838433810"><span class="h2">Medical necessity of off-label use of medications in pediatrics</span><span class="headingEndMark"> — </span>Use of second- or third-line agents and/or escalation of doses beyond those approved by the FDA may be appropriate and medically necessary for selected children with UC. The decision should be based on individual patient characteristics and clinical judgement by an expert clinician. In the United States, some insurance companies and payors have been denying coverage for these medically necessary therapies, stating that the use is "experimental," which usually is not the case. According to a position statement by the American Academy of Pediatrics: "The purpose of off-label use is to benefit the individual patient. Practitioners use their professional judgment to determine these uses. As such, the term 'off-label' does not imply an improper, illegal, contraindicated, or investigational use. Therapeutic decision-making must always rely on the best available evidence and the importance of the benefit for the individual patient" [<a href="#rid60">60</a>].</p><p>Substantial evidence supports a role for dose escalation, therapeutic drug monitoring, and utilization of drugs that are approved in adults in the management of pediatric UC. In many cases of severe or refractory IBD, off-label use (eg, high-dose <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, or, possibly, <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>) is medically necessary and is in the patient's best interest.</p><p>The evidence supporting these off-label uses is outlined in the above description of each drug. If the medically necessary treatment is denied by a payer, the clinician may advocate for the patient by providing medical details on the patient case and including relevant medical literature supporting the utilization of an off-label treatment [<a href="#rid81">81,82</a>]. However, the process to appeal an inappropriate insurance denial sometimes takes weeks to months and these delays are associated with increased rates of disease activity, as well as emergency department visits and hospitalizations. If the patient deteriorates, they may need to be readmitted for stabilization pending the insurance company's decision about whether they will pay for the medically necessary medication [<a href="#rid83">83,84</a>]. (See <a class="local">'Second-line options'</a> above and  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis", section on 'Escalating medical therapy ("rescue")'</a>.)</p><p class="headingAnchor" id="H3110448261"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The disease course of UC varies markedly and is only partially correlated with disease severity at presentation. Data about short-term (52-week) outcomes come from a multicenter registry study that included more than 400 subjects who were treated using a standardized protocol starting with either aminosalicylates or corticosteroids depending on disease severity, then advancing therapy as needed [<a href="#rid85">85</a>]. At presentation, most patients (83 percent) had extensive disease or pancolitis and 42 percent had mild disease severity (defined in this study as pediatric UC activity index [PUCAI] score &lt;45). After one year of therapy, 38 percent of subjects were in corticosteroid-free remission (98 percent on aminosalicylates alone and 2 percent on no therapy) and the remainder had advanced to immunomodulators (19 percent), anti-tumor necrosis factor (anti-TNF) antibodies (31 percent), or colectomy (6 percent). The best predictors of remission at one year were low disease severity and hemoglobin &gt;10 g/dL at baseline, and initial response to therapy (at week 4).</p><p class="headingAnchor" id="H39295927"><span class="h1">IMPORTANT HEALTH MAINTENANCE ISSUES</span><span class="headingEndMark"> — </span>Patients with inflammatory bowel disease (IBD) require close health supervision for a number of issues, which are discussed in detail in a separate topic review (see  <a class="medical medical_review" href="/z/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Nutritional status and growth failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection risk and immunizations – Because many patients are treated with immunosuppressive medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring for extraintestinal manifestations – Especially hepatobiliary and eye disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychological issues and support.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk of colorectal cancer – The risk for developing colorectal cancer in patients with UC increases with disease duration and is higher in those who have had extensive colitis, even if the disease is subsequently controlled. We suggest beginning surveillance colonoscopy for cancer screening starting 8 to 10 years after the diagnosis of UC and annually from the time of diagnosis in patients with comorbid sclerosing cholangitis [<a href="#rid26">26,86,87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transition to adult health care.</p><p></p><p class="headingAnchor" id="H2234496877"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113229.html" rel="external">"Society guideline links: Inflammatory bowel disease in children"</a>.)</p><p class="headingAnchor" id="H29010803"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86458.html" rel="external">"Patient education: Ulcerative colitis in children (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/1991.html" rel="external">"Patient education: Ulcerative colitis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H27249038"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Proctitis</strong> – For patients with ulcerative colitis (UC) that is limited to the distal rectum (proctitis), we suggest initial treatment with topical rectal 5-aminosalicylic acid (5-ASA, such as <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a>) or glucocorticoid enemas, foam, or suppositories, with or without concurrent oral 5-ASA, rather than treatment with systemic glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). If the symptoms respond to this treatment, we suggest maintenance therapy with either topical or oral 5-ASA rather than no treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The choice of medication and route of administration depends on the child and family's preference and on the patient's individual responsiveness to the treatment. (See <a class="local">'Proctitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colitis</strong> – For patients with left-sided UC (colitis primarily involving the rectum and descending colon), extensive disease (colitis extending proximal to the splenic flexure), or pancolitis (involving the entire colon), the initial treatment options depend on the severity of the disease. We select the medical therapy based on disease severity and escalate to more intensive therapies or consideration of surgical colectomy for patients whose disease is refractory to treatment. (See <a class="local">'Left-sided disease and pancolitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild</strong> – For patients with mild colitis (ie, fewer than four bowel movements daily without significant abdominal pain, anemia, or fever), we suggest initial treatment with oral 5-ASA (eg, <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a>) or <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, rather than systemic glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Mild disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate</strong> – For patients with moderate colitis (ie, more than four bloody bowel movements per day, usually with intermittent abdominal pain but without tenesmus or fever):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most such patients, we suggest initial treatment with oral glucocorticoids rather than oral 5-ASA or <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We typically use <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at a dose of 1 to 1.5 mg/kg/day (maximum dose 40 to 60 mg daily). However, for patients who are reluctant to use glucocorticoids, it is reasonable to offer a trial of 5-ASA, using doses at the high end of the range.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For those with poor fluid intake, abdominal pain, and/or lack of nutrition or for those who are unresponsive to oral glucocorticoid therapy, we suggest hospitalization and intravenous glucocorticoids. Another possibility is early use of a biologic agent (<a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>). (See <a class="local">'Moderate disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe</strong> – (See  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment goals</strong> – Disease activity and response to therapy is typically determined by changes in clinical symptoms but can be reliably measured using the pediatric UC activity index (PUCAI) score  (<a class="graphic graphic_table graphicRef69607" href="/z/d/graphic/69607.html" rel="external">table 4</a>) (<a class="calc calc_professional" href="/z/d/html/122272.html" rel="external">calculator 1</a>). In addition, resolution of active disease on endoscopy is increasingly used for documenting response to therapy. (See <a class="local">'Determination of response to therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Steroid-dependent</strong> <strong>colitis</strong> – For patients with steroid-dependent colitis (those who respond to glucocorticoid therapy but experience recurrent flares when the glucocorticoids are weaned):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest treatment with either <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, or an immunomodulator (<a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a> [6-MP] or <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> [AZA]), rather than colectomy or chronic treatment with corticosteroids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). All patients should undergo testing for thiopurine methyltransferase (TPMT) activity or genotype prior to initiating treatment with 6-MP or AZA. (See <a class="local">'Steroid-dependent disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who cannot be weaned from glucocorticoids despite the above medical therapies, the clinician should engage the patient and/or family in an informed decision about colectomy versus second-line medical therapy. Alternative medical therapies to be considered include <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a>, <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a>, <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, or <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>. (See  <a class="medical medical_review" href="/z/d/html/99093.html" rel="external">"Management of the hospitalized child or adolescent with acute severe ulcerative colitis", section on 'Subsequent steps for steroid-refractory disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The disease course of UC varies markedly and is only partly predicted by disease severity at baseline. After one year, approximately 40 percent of patients achieve corticosteroid-free remission (most on aminosalicylates) and most others advance to immunosuppressive or biologic therapy, while 5 to 10 percent undergo colectomy. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer risk</strong> – The risk for developing colorectal cancer in patients with UC increases with disease extent and duration. We suggest beginning surveillance colonoscopy for cancer screening starting 8 to 10 years after the diagnosis of UC. (See <a class="local">'Important health maintenance issues'</a> above.)</p><p></p><p class="headingAnchor" id="H2900770"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Tyler Burpee, MD, Alan Leichtner, MD, George H Russell, MD, MS, and Mala Setty, MD, who contributed to earlier versions of this topic review.</p><p>Dr. Bousvaros acknowledges the Clark, MacInnes, Rasmussen, Stefanis, Ward, and Wolfman families for support of his work.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci 2013; 58:519.</a></li><li><a class="nounderline abstract_t">Gryboski JD. Ulcerative colitis in children 10 years old or younger. J Pediatr Gastroenterol Nutr 1993; 17:24.</a></li><li><a class="nounderline abstract_t">Werlin SL, Grand RJ. Severe colitis in children and adolescents: diagnosis. Course, and treatment. Gastroenterology 1977; 73:828.</a></li><li><a class="nounderline abstract_t">Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135:1114.</a></li><li><a class="nounderline abstract_t">Levine A, de Bie CI, Turner D, et al. Atypical disease phenotypes in pediatric ulcerative colitis: 5-year analyses of the EUROKIDS Registry. Inflamm Bowel Dis 2013; 19:370.</a></li><li><a class="nounderline abstract_t">Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005; 146:35.</a></li><li><a class="nounderline abstract_t">Gupta N, Bostrom AG, Kirschner BS, et al. Presentation and disease course in early- compared to later-onset pediatric Crohn's disease. Am J Gastroenterol 2008; 103:2092.</a></li><li><a class="nounderline abstract_t">Ledder O, Catto-Smith AG, Oliver MR, et al. Clinical patterns and outcome of early-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014; 59:562.</a></li><li><a class="nounderline abstract_t">Oliva-Hemker M, Hutfless S, Al Kazzi ES, et al. Clinical Presentation and Five-Year Therapeutic Management of Very Early-Onset Inflammatory Bowel Disease in a Large North American Cohort. J Pediatr 2015; 167:527.</a></li><li><a class="nounderline abstract_t">Hyams JS. Extraintestinal manifestations of inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 1994; 19:7.</a></li><li><a class="nounderline abstract_t">Vecchi M, Meucci G, Gionchetti P, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001; 15:251.</a></li><li><a class="nounderline abstract_t">Navas-López VM, Blasco-Alonso J, Girón Fernández-Crehuet F, et al. Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine. Clin J Gastroenterol 2014; 7:320.</a></li><li><a class="nounderline abstract_t">Fehily SR, Martin FC, Kamm MA. Simple water-based tacrolimus enemas for refractory proctitis. JGH Open 2020; 4:561.</a></li><li><a class="nounderline abstract_t">Leichtner AM. Aminosalicylates for the treatment of inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1995; 21:245.</a></li><li><a class="nounderline abstract_t">Hochart A, Gower-Rousseau C, Sarter H, et al. Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. Gut 2016.</a></li><li><a class="nounderline abstract_t">Hyams J, Davis P, Lerer T, et al. Clinical outcome of ulcerative proctitis in children. J Pediatr Gastroenterol Nutr 1997; 25:149.</a></li><li><a class="nounderline abstract_t">Zeisler B, Lerer T, Markowitz J, et al. Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis. J Pediatr Gastroenterol Nutr 2013; 56:12.</a></li><li><a class="nounderline abstract_t">Hyams JS, Davis S, Mack DR, et al. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. Lancet Gastroenterol Hepatol 2017; 2:855.</a></li><li><a class="nounderline abstract_t">Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007; 133:423.</a></li><li><a class="nounderline abstract_t">Marcovitch L, Focht G, Carmon N, et al. Development and Validation of the TUMMY-UC: A Patient-Reported Outcome for Pediatric Ulcerative Colitis. Gastroenterology 2023; 164:610.</a></li><li><a class="nounderline abstract_t">Barreiro-de Acosta M, Vallejo N, de la Iglesia D, et al. Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. J Crohns Colitis 2016; 10:13.</a></li><li><a class="nounderline abstract_t">Kerur B, Litman HJ, Stern JB, et al. Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis. World J Gastroenterol 2017; 23:3322.</a></li><li><a class="nounderline abstract_t">Mack DR, Saul B, Boyle B, et al. Analysis of Using the Total White Blood Cell Count to Define Severe New-onset Ulcerative Colitis in Children. J Pediatr Gastroenterol Nutr 2020; 71:354.</a></li><li><a class="nounderline abstract_t">Pascarella F, Martinelli M, Miele E, et al. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009; 154:854.</a></li><li><a class="nounderline abstract_t">Martinelli M, Strisciuglio C, Veres G, et al. Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN study. Inflamm Bowel Dis 2014; 20:2219.</a></li><li><a class="nounderline abstract_t">Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67:257.</a></li><li><a class="nounderline abstract_t">Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021; 160:1570.</a></li><li><a class="nounderline abstract_t">Krzesiek E. Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children. Adv Clin Exp Med 2015; 24:815.</a></li><li><a class="nounderline abstract_t">Vuitton L, Peyrin-Biroulet L, Colombel JF, et al. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther 2017; 45:801.</a></li><li><a class="nounderline abstract_t">Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol 2015; 110:1324.</a></li><li><a class="nounderline abstract_t">Oliva S, Thomson M, de Ridder L, et al. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67:414.</a></li><li><a class="nounderline abstract_t">Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54:960.</a></li><li><a class="nounderline abstract_t">Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011; 33:672.</a></li><li><a class="nounderline abstract_t">Winter HS, Krzeski P, Heyman MB, et al. High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis. J Pediatr Gastroenterol Nutr 2014; 59:767.</a></li><li class="breakAll">Manufacturer's label for LIALDA, June 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022000s019lbl.pdf (Accessed on July 06, 2020).</li><li><a class="nounderline abstract_t">Quiros JA, Heyman MB, Pohl JF, et al. Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. J Pediatr Gastroenterol Nutr 2009; 49:571.</a></li><li><a class="nounderline abstract_t">Hanauer SB, Smith M. Critical drug appraisal: Olsalazine. Drug Ther Bull 1991; 21:57.</a></li><li><a class="nounderline abstract_t">Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther 2014; 39:1095.</a></li><li><a class="nounderline abstract_t">Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63:433.</a></li><li><a class="nounderline abstract_t">Turner D, Levine A, Kolho KL, et al. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report. J Crohns Colitis 2014; 8:1464.</a></li><li><a class="nounderline abstract_t">Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106:661.</a></li><li><a class="nounderline abstract_t">Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999; 44:1220.</a></li><li><a class="nounderline abstract_t">Kader HA, Mascarenhas MR, Piccoli DA, et al. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999; 28:54.</a></li><li><a class="nounderline abstract_t">Stenke E, Hussey S. Ulcerative colitis: management in adults, children and young people (NICE Clinical Guideline CG166). Arch Dis Child Educ Pract Ed 2014; 99:194.</a></li><li><a class="nounderline abstract_t">Cuffari C, Lake A. 6-Mercaptopurine in chronic ulcerative colitis: two steps forward with another step back? J Pediatr Gastroenterol Nutr 1999; 28:17.</a></li><li><a class="nounderline abstract_t">Aloi M, DʼArcangelo G, Bramuzzo M, et al. Effect of Early Versus Late Azathioprine Therapy in Pediatric Ulcerative Colitis. Inflamm Bowel Dis 2016; 22:1647.</a></li><li><a class="nounderline abstract_t">Suskind DL, Wahbeh G, Burpee T, et al. Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. J Pediatr Gastroenterol Nutr 2013; 56:277.</a></li><li><a class="nounderline abstract_t">Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. Gastroenterology 2017; 152:1901.</a></li><li><a class="nounderline abstract_t">Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012; 10:391.</a></li><li><a class="nounderline abstract_t">Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146:392.</a></li><li><a class="nounderline abstract_t">Croft NM, Faubion WA, Kugathasan S, et al. Efficacy and safety of adalimumab in pediatric patients with moderate to severe ulcerative colitis: Results of a randomized-controlled phase 3 study (OP140). United European Gastroenterol J 2020; 8:98.</a></li><li class="breakAll">Manufacturer's prescribing information for HUMIRA (2/2021). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125057s417lbl.pdf (Accessed on April 06, 2021).</li><li><a class="nounderline abstract_t">Volonaki E, Mutalib M, Kiparissi F, et al. Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis. Eur J Gastroenterol Hepatol 2015; 27:1425.</a></li><li><a class="nounderline abstract_t">Aloi M, Bramuzzo M, Arrigo S, et al. Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry. J Pediatr Gastroenterol Nutr 2018; 66:920.</a></li><li><a class="nounderline abstract_t">Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462.</a></li><li><a class="nounderline abstract_t">Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105:1133.</a></li><li><a class="nounderline abstract_t">Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004; 99:1122.</a></li><li><a class="nounderline abstract_t">Hyams JS, Lerer T, Mack D, et al. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol 2011; 106:981.</a></li><li><a class="nounderline abstract_t">Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59:1363.</a></li><li><a class="nounderline abstract_t">Frattarelli DA, Galinkin JL, Green TP, et al. Off-label use of drugs in children. Pediatrics 2014; 133:563.</a></li><li><a class="nounderline abstract_t">Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369:699.</a></li><li><a class="nounderline abstract_t">Singh N, Rabizadeh S, Jossen J, et al. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22:2121.</a></li><li><a class="nounderline abstract_t">Jossen J, Kiernan BD, Pittman N, Dubinsky MC. Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2020; 70:304.</a></li><li><a class="nounderline abstract_t">Christensen B, Gibson PR, Micic D, et al. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2019; 17:486.</a></li><li><a class="nounderline abstract_t">Moens A, Verstockt B, Alsoud D, et al. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD. Inflamm Bowel Dis 2022; 28:1135.</a></li><li><a class="nounderline abstract_t">Conrad MA, Stein RE, Maxwell EC, et al. Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22:2425.</a></li><li><a class="nounderline abstract_t">Ledder O, Assa A, Levine A, et al. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis 2017; 11:1230.</a></li><li><a class="nounderline abstract_t">Hyams JS, O'Brien CD, Padgett L, et al. Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results. Crohns Colitis 360 2020; 2:otaa063.</a></li><li><a class="nounderline abstract_t">Herfarth H, Barnes EL, Valentine JF, et al. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology 2018; 155:1098.</a></li><li><a class="nounderline abstract_t">Chande N, Wang Y, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2014; :CD006618.</a></li><li><a class="nounderline abstract_t">Lazzerini M, Martelossi S, Magazzù G, et al. Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives: Pilot Randomized Clinical Trial. Inflamm Bowel Dis 2015; 21:1739.</a></li><li><a class="nounderline abstract_t">Lazzerini M, Martelossi S, Magazzù G, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA 2013; 310:2164.</a></li><li class="breakAll">US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death?utm_medium=email&amp;utm_source=govdelivery (Accessed on March 25, 2022).</li><li><a class="nounderline abstract_t">Moore H, Dubes L, Fusillo S, et al. Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2021; 73:e57.</a></li><li><a class="nounderline abstract_t">Constant BD, Baldassano R, Kirsch J, et al. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2022; 75:724.</a></li><li><a class="nounderline abstract_t">Berinstein JA, Sheehan JL, Dias M, et al. Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study. Clin Gastroenterol Hepatol 2021; 19:2112.</a></li><li><a class="nounderline abstract_t">Collen LV. Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn's Disease. Inflamm Bowel Dis 2023; 29:1175.</a></li><li><a class="nounderline abstract_t">Panaccione R, Danese S, Sandborn WJ, et al. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Aliment Pharmacol Ther 2020; 52:1658.</a></li><li><a class="nounderline abstract_t">Dayan JR, Dolinger M, Benkov K, et al. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center. J Pediatr Gastroenterol Nutr 2019; 69:61.</a></li><li><a class="nounderline abstract_t">Dhaliwal J, McKay HE, Deslandres C, et al. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study. Aliment Pharmacol Ther 2021; 53:1300.</a></li><li><a class="nounderline abstract_t">Bhat S, Zahorian T, Robert R, Farraye FA. Advocating for Patients With Inflammatory Bowel Disease: How to Navigate the Prior Authorization Process. Inflamm Bowel Dis 2019; 25:1621.</a></li><li><a class="nounderline abstract_t">Jaff JC, Arnold J, Bousvaros A. Effective advocacy for patients with inflammatory bowel disease: communication with insurance companies, school administrators, employers, and other health care overseers. Inflamm Bowel Dis 2006; 12:814.</a></li><li><a class="nounderline abstract_t">Constant BD, de Zoeten EF, Stahl MG, et al. Delays Related to Prior Authorization in Inflammatory Bowel Disease. Pediatrics 2022; 149.</a></li><li><a class="nounderline abstract_t">Kahn SA, Bousvaros A. Denials, Dilly-dallying, and Despair: Navigating the Insurance Labyrinth to Obtain Medically Necessary Medications for Pediatric Inflammatory Bowel Disease Patients. J Pediatr Gastroenterol Nutr 2022; 75:418.</a></li><li><a class="nounderline abstract_t">Hyams JS, Davis Thomas S, Gotman N, et al. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet 2019; 393:1708.</a></li><li><a class="nounderline abstract_t">Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012; 55:93.</a></li><li><a class="nounderline abstract_t">Murthy SK, Feuerstein JD, Nguyen GC, Velayos FS. AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. Gastroenterology 2021; 161:1043.</a></li></ol></div><div id="topicVersionRevision">Topic 5871 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22926499" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8350209" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ulcerative colitis in children 10 years old or younger.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/408222" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Severe colitis in children and adolescents: diagnosis. Course, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18725221" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22570259" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Atypical disease phenotypes in pediatric ulcerative colitis: 5-year analyses of the EUROKIDS Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15644819" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18796101" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Presentation and disease course in early- compared to later-onset pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24979317" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical patterns and outcome of early-onset inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25982142" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical Presentation and Five-Year Therapeutic Management of Very Early-Onset Inflammatory Bowel Disease in a Large North American Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7965480" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Extraintestinal manifestations of inflammatory bowel disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11148445" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26185880" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32782938" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Simple water-based tacrolimus enemas for refractory proctitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8523207" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Aminosalicylates for the treatment of inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27489240" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9252900" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical outcome of ulcerative proctitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22847466" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28939374" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17681163" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36539016" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Development and Validation of the TUMMY-UC: A Patient-Reported Outcome for Pediatric Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26351390" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28566893" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32520830" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Analysis of Using the Total White Blood Cell Count to Define Severe New-onset Ulcerative Colitis in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19230908" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Impact of Clostridium difficile infection on pediatric inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25268634" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30044357" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33359090" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26768632" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28112419" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26303131" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30130311" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15951542" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21255059" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25419597" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25419597" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19633577" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Critical drug appraisal: Olsalazine</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24641622" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23436336" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24958064" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21407187" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10389700" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9890469" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24821990" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Ulcerative colitis: management in adults, children and young people (NICE Clinical Guideline CG166).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9890462" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : 6-Mercaptopurine in chronic ulcerative colitis: two steps forward with another step back?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27271489" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of Early Versus Late Azathioprine Therapy in Pediatric Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23059643" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28193515" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22155755" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24512909" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy and safety of adalimumab in pediatric patients with moderate to severe ulcerative colitis: Results of a randomized-controlled phase 3 study (OP140)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Efficacy and safety of adalimumab in pediatric patients with moderate to severe ulcerative colitis: Results of a randomized-controlled phase 3 study (OP140)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26426835" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29315163" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16339095" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Infliximab for induction and maintenance therapy for ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20145610" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180735" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21224840" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20587545" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24567009" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Off-label use of drugs in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23964932" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Vedolizumab as induction and maintenance therapy for ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27542130" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31738290" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29751166" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34751766" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27598742" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28605483" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36777743" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29964043" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25162749" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Methotrexate for induction of remission in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26185909" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives: Pilot Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24281461" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24281461" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34091545" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36122389" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34048936" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36933200" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33086438" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31058718" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33909911" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30753551" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Advocating for Patients With Inflammatory Bowel Disease: How to Navigate the Prior Authorization Process.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16917236" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effective advocacy for patients with inflammatory bowel disease: communication with insurance companies, school administrators, employers, and other health care overseers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35190811" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Delays Related to Prior Authorization in Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35836325" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Denials, Dilly-dallying, and Despair: Navigating the Insurance Labyrinth to Obtain Medically Necessary Medications for Pediatric Inflammatory Bowel Disease Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30935734" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22516861" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34416977" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
